LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly announces FDA Breakthrough Therapy designation for sofetabart mipitecan in pre-market
Eli Lilly announced that the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan (LY4170156), for the treatment of...
Eli Lilly Solidifies Lead in Weight-Loss Drug Market Amid Fierce Competition
Eli Lilly is extending its lead over Novo Nordisk in the rapidly growing weight-loss drug market. Analysts cite the superior effectiveness of Lilly’s Zepbound...
Eli Lilly Shares Plunge Nearly 5% to Hit Four-Week Low Amid Sharp Selling Pressure
Eli Lilly shares suffered a sharp decline on January 15, falling by as much as 4.87% despite overall U.S. markets advancing during the session. The stock...
🔴 Eli Lilly is trading 3% down today after FDA delayed decision on weight-loss pill
Eli Lilly is trading at $1041.07 (-3.00%) after the FDA announced a delay in the decision timeline for its weight-loss pill. * The FDA decision on the drug...
Eli Lilly Shares Decline After FDA Delays Decision on Oral Weight-Loss Pill
The U.S. Food and Drug Administration (FDA) delayed its decision on Eli Lilly’s new oral weight-loss pill. The agency set a new target date of April 10,...
BMO Capital Markets Reiterates 'Buy' Rating on Eli Lilly, Citing Strength in Weight-Loss and Pipeline
BMO Capital Markets reaffirmed its 'outperform' rating on Eli Lilly (LLY). The firm set a $1,200 price target, suggesting a 12% upside from current...
Eli Lilly CEO Highlights Positive Outlook at JPMorgan Healthcare Conference
Eli Lilly CEO Dave Ricks presented at the JPMorgan Healthcare Conference. The transcript became available on January 14, 2026. Ricks set a positive tone for...
Eli Lilly and Nvidia Announce $1 Billion AI Collaboration for Drug Discovery
Eli Lilly and Nvidia launched a collaboration focused on applying advanced artificial intelligence (AI) to drug development. The initiative is backed by a...
Eli Lilly CFO Confirms Q2 2026 Target for FDA Approval of Oral Obesity Pill Orforglipron
Eli Lilly CFO Lucas Montarce confirmed the company's timeline for its oral obesity drug, orforglipron, at the JPMorgan Healthcare Conference. Lilly targets...
Eli Lilly and Nvidia Announce $1B AI Lab for Drug Discovery
Eli Lilly and Nvidia announced a major collaboration to launch an artificial intelligence co-innovation lab. Unveiled at the J.P. Morgan Healthcare Conference,...
Eli Lilly Reportedly Prepares €15 Billion Bid for French Biotech Abivax
Eli Lilly is reportedly preparing a €15 billion offer to acquire French biotechnology firm Abivax. The U.S. pharmaceutical giant has not yet submitted a formal...
Eli Lilly's Taltz and Zepbound Combination Therapy Succeeds in Phase 3b Psoriatic Arthritis Trial
Eli Lilly released positive topline results from the Phase IIIb TOGETHER-PsA study. The trial combined the arthritis drug Taltz (ixekizumab) with the...
Eli Lilly shares little changed in pre-market as Zacks names it 'Bull of the Day'
Eli Lilly shares are trading modestly higher pre-market at $1088.85 after Zacks Equity Research selected the company as its “Bull of the Day,” emphasizing its...
Eli Lilly shares little changed as insider sale and obesity-pill optimism balance out
Eli Lilly received a significant boost after UBS raised its price target to $1,250, maintaining a bullish outlook on the company's robust obesity pipeline,...
Eli Lilly shares little changed in after-hours trading ahead of January 9 session
A recent Form 4 filing revealed that Lilly Endowment Inc. executed a significant insider sale on January 7, offloading 293,446 shares of Eli Lilly for...
Eli Lilly Expands AI Drug Discovery and Immunology Pipeline with New Collaboration and Potential Acquisition
Eli Lilly and Company announced a collaboration with BigHat Biosciences to advance its machine-learning biologics discovery platform, TuneLab. BigHat will...
Eli Lilly Announces Major Obesity Drug Partnership and Is in Talks for $1B+ Acquisition, Fueling Stock Surge
Eli Lilly and Company stock surged on January 7, 2026. The rise followed two major announcements bolstering its position in the high-growth obesity drug...
🟢 LLY is trading 3.7% up today on reports of $1B+ Ventyx Biosciences acquisition talks
LLY is trading at $1103.03 (+3.7%) amid reports of advanced talks to acquire Ventyx Biosciences for over $1 billion. * Ventyx's experimental pills target...
Eli Lilly Expands Obesity Pipeline with $1.3B Nimbus Therapeutics Collaboration
Eli Lilly and Company announced a multi-year collaboration with Nimbus Therapeutics. The partnership focuses on developing a novel preclinical oral obesity...
Eli Lilly Slashes Mounjaro Price in China by Nearly 70%
Eli Lilly drastically cut the price of its weight-loss drug, Mounjaro, in the Chinese market. The monthly cost for the lowest dose fell nearly 70%. The price...